Successful Human Clinical Trial of Chrono Therapeutics, Inc.'s Drug/Device Combination Product - ChronoDose(TM)
BASEL, Switzerland and TRENTON, N.J., May 3 /PRNewswire/ -- Chrono Therapeutics Inc. (CTI) announced today the successful completion of its first phase human clinical trial of its programmable, pulsatile, passive transdermal drug/device combination product: ChronoDose(TM). CTI intends to publish this clinical data in leading scientific and medical journals by year end.